Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Key clinical trial weight loss results non-diabetic adults with obesity Semaglutide 2.4 mg (Wegovy) STEP 1 68 weeks n=1,961 ~15% mean weight loss ~33% achieved 20% loss vs 2.4% placebo Tirzepatide 15 mg (Zepbound) SURMOUNT-1 72 weeks n=2,539 ~21% mean weight loss ~57% achieved 20% loss vs 3.1% placebo Head-to-head SURMOUNT-5 (2025) 72 weeks direct comparison ~6 percentage point advantage for tirzepatide over semaglutide statistically significant Fig
Common side effects include mild gastrointestinal issues such as nausea, vomiting, diarrhea, or constipation
It is calculated based on a Morningstar risk-adjusted return measure that accounts for variation in a managed products monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance
This allows more sustained weight loss, but may require more long term use of the medication at lower dosing in order to avoid rebound weight gain
